Ms Kiran Mazumdar-Shaw, Chairman & MD, Biocon
Biocon outperformed the 6 percent growth of the Indian pharmaceutical industry with a 12 percent growth in biopharmaceutical revenues.
In August 2013, Biocon launched ALZUMAb, a novel "first-in-class" biologic drug, for chronic plaque psoriasis in India. ALZUMAb is the second novel biologic launched by Biocon and represents the first biological drug for psoriasis to be researched, developed, and manufactured in India.
Biocon also launched its CANMAb in January 2014. This is believed to be the world's lowest priced trastuzumab for the treatment of HER2-positive metastatic breast cancer in India.
The company witnessed many collaborative partnerships during the fiscal year. It entered into a licensing and collaborative partnership with Quark Pharmaceuticals to co-develop, manufacture and commercialize QPI-1007, a novel siRNA drug candidate for ophthalmic conditions, in India and other key markets.
It also signed a pact with US-based Advaxis for the co-development and commercialization of ADXS-HPV, a novel cancer immunotherapy for the treatment of human papillomavirus (HPV), associated with cervical cancer in women. Biocon's strategic tie-up with CytoSorbents for the sale of CytoSorb, for sepsis management, in India and other selected Asian markets was also a major milestone for the company.
Uncertainty over clinical trials continued to pose a serious challenge in FY13-14. The hostile clinical trials environment in India has forced Biocon to take some clinical development programs overseas, which in turn is expected to push up its R&D spend.
Biocon was also listed 6th among 10 leading biopharma employers in the world, according to a survey conducted by the prestigious Science magazine in 2013.
Another feather in the cap for Biocon was establishing the Biocon Academy as a Centre of Excellence for advanced learning in biosciences. In partnership with the Keck Graduate Institute of Claremont (California, USA), Biocon Academy flagged-off the first Biocon KGI program in Biosciences.